Director/PDMR Shareholding

RNS Number : 0676F
GlaxoSmithKline PLC
15 February 2018
 

                

GlaxoSmithKline plc (the 'Company')

 

2018 Award under the Deferred Investment Award Programme

Notional Award

 

On 14 February, 2018 the Company granted an award over notional Ordinary Shares to a Person Discharging Managerial Responsibilities ('PDMR') under the GlaxoSmithKline Deferred Investment Award programme. 

 

The PDMR joined the Company in September 2017 and the award is made under the terms of the employment offer.  The award will vest 25% on each of 4 September, 2020, 4 September, 2021, 4 September, 2022, and 4 September, 2023.  

 

Under the programme, awards are made over notional Ordinary Shares with vesting phased over a specified period to provide long-term alignment with shareholders.  Vesting is subject to the PDMR not having served the Company notice or having been terminated by the Company for cause.  Notional dividends will accrue on the award during the vesting period through dividend reinvestment in additional notional shares.  On vesting, the award and accrued dividends will be paid in cash.  Executive Directors are not eligible to receive awards under the programme.  

 

 

 

 

 

Transaction notification

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr L Miels

b)

Position/status

President, Global Pharmaceuticals

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

b)

Nature of the transaction

A restricted award of notional Ordinary Shares under the Company's Deferred Investment Award programme.

 

c)

Price(s) and

volume(s)

 

Price(s)

Volume(s)

 

 

£15.00

90,266.667

 

 

 

 

 

d)

Aggregated information

n/a (single transaction)

Aggregated volume Price

 

e)

Date of the transaction

2018-02-14

f)

Place of the transaction

 

n/a

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHVELFFVLFBBBD

Companies

GSK (GSK)
UK 100

Latest directors dealings